Utilizing a GnRH-based chimeric protein for the detection of adenocarcinoma

International Journal of Oncology

Volumn 27, Issue 1, 2005, Pages 143-148

  Lichtenstein, Michal ^a   Ben Yehudah, Ahmi ^a   Belostotsky, Ruth ^a   Eaveri, Ronen ^a   Sabag, Ofra ^a   Grodzovski, Inna ^a   Lorberboum Galski, Haya ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

Adenocarcinoma; Binding assays; Cancer detection; Chimeric proteins; GnRH Caspase3

Indexed keywords

CASP3 PROTEIN, HUMAN; CASPASE; CASPASE 3; GONADORELIN; HYBRID PROTEIN;

ADENOCARCINOMA; ARTICLE; BINDING SITE; CELL SEPARATION; CELL SURVIVAL; CHEMISTRY; CONFOCAL MICROSCOPY; DOSE RESPONSE; FLOW CYTOMETRY; HUMAN; METABOLISM; PLASMID; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN BINDING; SENSITIVITY AND SPECIFICITY; TUMOR CELL LINE;

ADENOCARCINOMA; BINDING SITES; CASPASE 3; CASPASES; CELL LINE, TUMOR; CELL SEPARATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLOW CYTOMETRY; GONADOTROPIN-RELEASING HORMONE; HUMANS; MICROSCOPY, CONFOCAL; PLASMIDS; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; SENSITIVITY AND SPECIFICITY;

EID: 24644464680     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.27.1.143     Document Type: Article

References (23)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E and Thun MJ: Cancer statistics, 2003. CA Cancer J Clin 53: 5-26, 2003.
2. Nechushtan A, Yarkoni S, Marianovsky I and Lorberboum- Galski H: Adenocarcinoma cells are targeted by the new GnRHPE66 chimeric toxin through specific gonadotropin-releasing hormone binding sites. J Biol Chem 272: 11597-11603, 1997.
3. Ben-Yehudah A, Yarkoni S, Nechushtan A, Belostotsky R and Lorberboum-Galski H: Linker-based GnRH-PE chimeric proteins inhibit cancer growth in nude mice. Med Oncol 16: 38-45, 1999.
4. Azar Y and Lorberboum-Galski H: GnRH-Bik/Bax/Bak chimeric proteins target and kill adenocarcinoma cells; the general use of pro-apoptotic proteins of the Bcl-2 family as novel killing components of targeting chimeric proteins. Apoptosis 5: 531-542, 2000.
5. Ben-Yehudah A, Aqeilan R, Robashkevich D and Lorberboum- Galski H: Using apoptosis for targeted cancer therapy by a new gonadotropin releasing hormone-DNA fragmentation factor 40 chimeric protein. Clin Cancer Res 9: 1179-1190, 2003.
6. Ben-Yehudah A, Belostotsky R, Aqeilan R, Azar Y, Steinberger I, Fishman A, et al. Chimeric proteins: a novel approach for eliminating specific cell populations for targeted human therapy. In: Chimeric proteins: A novel approach for eliminating specific cell populations for targeted human therapy. Lorberboum-Galski H and Lazarovici P (eds). Harwood Academic Publishers, London and New York, pp 148-167, 2002.
7. Niv R, Cohen CJ, Denkberg G, Segal D and Reiter Y: Antibody engineering for targeted therapy of cancer: recombinant Fvimmunotoxins. Curr Pharm Biotechnol 2: 19-46, 2001.
8. Reiter Y: Recombinant immunotoxins in targeted cancer cell therapy. Adv Cancer Res 81: 93-124, 2001.
9. Ben-Yehudah A, Belostotsky R, Lichtenstein M, Aqeilan R, Abady R and Lorberboum Galski H: Chimeric proteins as candidates for cancer treatment. Drugs Future 27: 851-861, 2002.
10. King JA and Millar RP: Evolutionary aspects of gonadotropinreleasing hormone and its receptor. Cell Mol Neurobiol 15: 5-23, 1995.
11. Millar RP: GnRH II and type II GnRH receptors. Trends Endocrinol Metab 14: 35-43, 2003.
12. Ben-Yehudah A, Prus D and Lorberboum-Galski H: I.V. Administration of L-GNRH-PE66 efficiently inhibits growth of colon adenocarcinoma xenografts in nude mice. Int J Cancer 92: 263-268,2001.
13. Montironi R, Mazzucchelli R and Scarpelli M: Molecular techniques and prostate cancer diagnostic. Eur Urol 44: 390-400, 2003.
14. Nishizuka S, Chen ST, Gwadry FG, Alexander J, Major SM, Scherf U, et al: Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res 63: 5243-5250, 2003.
15. Souriau C and Hudson PJ: Recombinant antibodies for cancer diagnosis and therapy. Expert Opin Biol Ther 3: 305-318, 2003.
16. Hudson PJ and Souriau C: Recombinant antibodies for cancer diagnosis and therapy. Expert Opin Biol Ther 1: 845-855, 2001.
17. Stevanovic S: Identification of tumour-associated T-cell epitopes for vaccine development. Nat Rev Cancer 2: 514-520, 2002.
18. Michael A and Pandha HS: Renal-cell carcinoma: tumour markers, T-cell epitopes, and potential for new therapies. Lancet Oncol 4: 215-223, 2003.
19. Allen TM: Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2: 750-763, 2002.
20. Ben-Yehudah A, Aqeilan R, Belostotsky R, Azar Y and Lorberboum-Galski H: Utilizing chimeric proteins for exploring the cellular fate of endogenous proteins. Biochem Biophys Res Commun 290: 332-338, 2002.
21. Steinberger I, Ben-Bassat H, Hochberg E and Lorberboum- Galski H: Interleukin-2 (IL-2) receptor alpha, beta and gamma subunit expression as a function of B-cell lineage ontogeny: the use of IL-2-PE66(4Glu) to characterize internalization via IL-2 receptor subunits. Scand J Immunol 46: 129-136, 1997.
22. Lorberboum-Galski H: ligand-receptor interaction studied with chimeric proteins. In: Chimeric proteins: A novel approach for eliminating specific cell populations for targeted human therapy. Lorberboum-Galski H and Lazarovici P (eds). Harwood Academic Publishers, London and New York, ppl35-147, 2002.
23. Belostotsky R and Lorberboum-Galski H: Utilizing Fe epsilon-Bak chimeric protein for studying IgE-Fc epsilon RI interactions. Clin Immunol 110: 89-99, 2004.